Storys zum Thema Bevacizumab
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- Ein Dokumentmehr
Press release: STADA and Xbrane launch ranibizumab to support patient access in Europe
STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...
Ein DokumentmehrPress release: STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis® - European Commission grants pan-EU marketing authorization for Ximluci® biosimilar referencing Lucentis® (ranibizumab) - Paves way for European ...
Ein DokumentmehrPress release: Strong in-market performance leads STADA to double-digit growth
Strong in-market performance leads STADA to double-digit growth - Continued strong organic market-share gains across key European markets, supported by several launches - Adjusted Group sales advance by 15% while adjusted EBITDA improve by 23% in first half of 2022 - STADA CEO Peter Goldschmidt: “In ...
Ein DokumentmehrPress release: STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab
STADA and Alvotech broaden European patients’ options by launching a high-concentration, citrate-free adalimumab - Offers a comprehensive range of presentations to the EU adalimumab biosimilars market - Adalimumab marks the first molecule ...
Ein Dokumentmehr